NEXGEL's BioNX Acquisition: A Desperate Bet to Triple Revenue and Turn Profitable
The small-cap hydrogel maker closes a regenerative medicine deal from Celularity, funded by a convertible note and a strategic partner, while the stock plunges and revenue stays flat.
NXGL · Earnings Call · 2026-05-15
The Pivot: From Hydrogels to Regenerative Medicine
NEXGEL's latest shareholder call was less an earnings update than a declaration of reinvention. The company has closed the acquisition of the BioNX division from Celularity, a portfolio of six commercial-stage regenerative biomaterial products with a decade of clinical use and existing reimbursement pathways. Management frames this as a step change:
The BioNX portfolio includes 6 established regenerative biomaterial products positioning us squarely within 1 of the fastest growing segments of health care.
They project the deal will roughly triple annual revenue to $35 million and be immediately accretive. To lead the effort, they've hired Dave Hazard as VP of sales and brought in a new CFO, Ian Blackman — a veteran M&A leader who will run integration. The financing was led by Sequence LifeScience, which injected $5.5 million and replaced a distressed financial lender with a long-term strategic partner. The narrative has clearly shifted from consumer beauty and hydrogel manufacturing to BioNX division and the broader regenerative medicine landscape.
Understandably, the Street is skeptical. The company's recent 90-day price action shows a -42% return, and the stock sits 56% below its April peak. The full history is worse: -90% from its 2024 high. The market cap is now roughly $5 million, a fraction of the promised $35 million revenue run rate. This is a classic micro-cap transformation story — high risk, high potential, and a management team that has consistently missed its own profitability targets.
The Numbers: Flat Revenue, High Hopes
First-quarter 2026 revenue was $2.65 million, down slightly from $2.81 million a year ago. The company attributes the flatness to a weak Silly George (the beauty brand) offset by growth in contract manufacturing and Medagel. Cash on hand is a slim $1.8 million. They raised $13.8 million — $8.8 million in cash and a $5 million convertible note delivered to Celularity — to fund the acquisition and working capital. The convertible note carries a 10% coupon and 18-month maturity, and with a conversion price of $0.60 and 50% warrant coverage, full conversion would add roughly 30 million shares to the existing float.
Fundamentally, the company is burning cash. Operating income and net income are both negative, with net income at -$927,000 in the latest quarter. Gross margin sits at 40%, but that's down 2.3 points year-over-year. Liabilities to assets have jumped to 61% from 47% a year ago, reflecting the new debt. The revenue trend is basically flat — Total revenue has hovered around $3 million for five quarters, and the year-over-year change is -6%. The company is betting everything on the acquisition to deliver a step change in scale and profitability, but so far the numbers don't show it.
Recurring Concerns: The Struggle to Turn Profitable
Analysts and private investors on the call pressed management on the offering, the legacy business, and the timeline to profitability. When asked why the legacy product lines had stopped growing, CEO Adam Levy admitted: “Yeah. It is. We do not expect it to stay flat.” — Adam R. Levy, Chief Executive Officer · 2026-05-15 He pointed to a recovery in April and new product launches, but the underlying message is that the old business has stagnated. Wound care, which had been a rising theme in the prior quarter, has been overshadowed by the BioNX narrative. The company is clearly repositioning itself as a regenerative medicine player, leaving the consumer and wound care themes behind.
The integration timeline is also a concern. Adam noted: “So we are really now just getting the contracts back and guys are going out there.” — Adam R. Levy, Chief Executive Officer · 2026-05-15 Only half a quarter of BioNX revenue will be recognized in Q2, and the sales force is only now ramping. This is a familiar pattern — in previous conferences, management promised EBITDA positive by year-end, but that milestone has repeatedly slipped. In the April call, they modeled EBITDA of $4-4.5 million on $22-23 million revenue: “if we did $22 million to $23 million, shows about $4 million to $4.5 million of EBITDA” — Adam Levy, Chief Executive Officer · 2026-04-21 But back in November, they acknowledged flat growth: “we appear to be and we are flat from third quarter last year to third quarter this year.” — Adam Levy, Chief Executive Officer · 2025-11-11
The company's commercial growth now hinges entirely on the BioNX portfolio and the ability to scale a surgical sales force in a competitive regenerative medicine market. The products are already approved in ~500 hospitals, but as the CEO admitted, the sales force had been dormant under Celularity's financial troubles. It's a credible story on paper, but execution risk is extreme for a company with $1.8 million in cash and a stock that has lost 90% of its value. The offering is nearly closed, and the company says it will announce completion soon — but investors remain on edge.
This is a make-or-break quarter for NEXGEL. If the BioNX integration delivers even a fraction of the promised $35 million run rate, the stock could re-rate dramatically. But the evidence so far — flat revenue, negative profitability, and a heavily diluted share count — suggests the market is right to be cautious. The story is compelling, but the numbers are not yet there.